Orphazyme opens US headquarters in Chicago and appoints executives

Ahead of what will most likely be a 2021 launch of the drug arimoclomol, Orphazyme has officially established a Chicago-based headquarters.

Orphazyme's CEO Kim Stratton. | Photo: Orphazyme / PR

Danish biopharmaceutical firm Orphazyme has chosen Chicago to house its US head office, after the firm went on the US stock market and will launch its first drug in the new year, according to the firm's press statement.

Orphazyme's CEO Kim Stratton says the choice fell on Chicago because this location brings the company closer to collaborative partners and other stakeholders in the US.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today